0001127602-19-030387.txt : 20191010 0001127602-19-030387.hdr.sgml : 20191010 20191010170318 ACCESSION NUMBER: 0001127602-19-030387 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191008 FILED AS OF DATE: 20191010 DATE AS OF CHANGE: 20191010 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Scanlan Jacqueline CENTRAL INDEX KEY: 0001713517 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14041 FILM NUMBER: 191146600 MAIL ADDRESS: STREET 1: HAEMONETICS CORPORATION STREET 2: 400 WOOD ROAD CITY: BRAINTREE STATE: MA ZIP: 02184 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HAEMONETICS CORP CENTRAL INDEX KEY: 0000313143 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042882273 STATE OF INCORPORATION: MA FISCAL YEAR END: 0328 BUSINESS ADDRESS: STREET 1: 400 WOOD RD CITY: BRAINTREE STATE: MA ZIP: 02184 BUSINESS PHONE: 7818487100 MAIL ADDRESS: STREET 1: 400 WOOD ROAD CITY: BRAINTREE STATE: MA ZIP: 02184 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2019-10-08 0000313143 HAEMONETICS CORP HAE 0001713517 Scanlan Jacqueline 400 WOOD ROAD BRAINTREE MA 02184 1 SVP, Global Human Resources Common Stock 2019-10-08 4 S 0 2295 122.34 D 7604 D Common Stock 2019-10-09 4 S 0 300 122.37 D 7304 D Common Stock 2019-10-09 4 S 0 1230 123.57 D 6074 D Common Stock 2019-10-09 4 S 0 1379 124.61 D 4695 D Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain performance share units previously reported in Table I on October 8, 2019. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This number includes unvested restricted stock units previously reported. Transaction pursuant to an existing 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.01 to $122.75, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.23 to $124.22, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.28 to $124.87, inclusive. /s/ Thomas V. Powers, attorney-in-fact for Ms. Scanlan 2019-10-10